Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem, Inc. received an amended ownership report from Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, stating beneficial ownership of 995,026 common shares, or 1.3% of the company’s outstanding stock as of December 31, 2025. These shares are held through an investment fund managed by Point72 Asset Management, with voting and investment power shared among the reporting entities. The filers certify that the position is not held for the purpose of changing or influencing control of Verastem.
RTW Investments and Roderick Wong reported beneficial ownership of 7,836,346 shares of Verastem common stock, representing 9.9% of the class. All voting and dispositive power over these shares is shared, with no sole authority reported by either party.
The ownership figure assumes the exercise of warrants held by the reporting persons to purchase 1,260,040 shares, subject to a 9.99% ownership cap in the warrant terms. The percentage is based on 66,776,006 shares outstanding as of November 3, 2025, plus 10,405,863 shares issued in a later public offering and the warrant shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem.
Balyasny Asset Management and affiliates report a 6.18% beneficial stake in Verastem Inc. common stock. The group reports beneficial ownership of 4,767,154 shares, consisting of 3,195,726 shares and 1,571,428 shares issuable upon exercise of warrants that are subject to a 9.99% beneficial ownership blocker.
The percentage is based on 77,154,709 Verastem shares outstanding as of November 17, 2025. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Verastem.
Nantahala Capital Management, LLC and its principals report a significant but sub‑5% stake in Verastem, Inc. They disclose beneficial ownership of 3,795,473 shares of Verastem common stock, representing 4.72% of the outstanding class as of December 31, 2025.
The filing states that Nantahala, Wilmot B. Harkey, and Daniel Mack share voting and dispositive power over these shares and have no sole voting or dispositive authority. They certify that the securities were acquired and are held in the ordinary course of business, not to change or influence control of Verastem.
Verastem, Inc. President and CEO Dan Paterson reported a small sale of company stock tied to tax withholding. On February 4, 2026, he sold 970 shares of common stock at $6.69 per share to satisfy statutory withholding for vested restricted stock units.
After this transaction, Paterson directly held 612,919 shares of Verastem common stock, indicating he retains a substantial equity stake despite the routine tax-related sale.
Verastem, Inc. filed a current report describing two related communications to the market. The company issued a press release with preliminary financial results for the quarter and full fiscal year ended December 31, 2025. These preliminary figures give an early view of Verastem’s recent operating performance.
In the same press release, Verastem also outlined its key strategic priorities for 2026, providing an overview of management’s focus areas for the coming year. The press release is furnished as an exhibit to the report, which is signed by Chief Executive Officer Daniel W. Paterson.
Verastem, Inc. Chief Financial Officer receives equity grant in the form of 16,665 shares of Common Stock on January 21, 2026, reported at a price of $0.00 per share as an award, not an open-market purchase. These shares arise from restricted stock units (RSUs) granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock.
The RSUs vest in three equal annual installments of approximately 33.3% on each of the first three anniversaries of January 21, 2026, becoming fully vested on January 21, 2029, as long as the CFO continues to serve as an employee or other service provider on each vesting date. Following this grant, the CFO directly beneficially owns 121,384 shares of Verastem common stock.
Verastem, Inc. reported an equity award to its President and CEO, Dan Paterson. On January 21, 2026, he was granted 213,785 shares of Verastem common stock in the form of restricted stock units (RSUs) at a price of $0.00 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. Following this grant, he beneficially owns 613,889 shares of common stock directly.
The RSUs are scheduled to vest over three years. They vest as to 33.3% of the award on each of the first three anniversaries of January 21, 2026, so that the grant is fully vested on January 21, 2029. Vesting requires that Paterson continue to serve as an employee or other service provider to Verastem on each vesting date.
Verastem, Inc. (VSTM) insider Daniel Calkins has filed notice of a planned stock sale under Rule 144. The filing covers up to 5,039 shares of Verastem common stock to be sold through Shareworks by Morgan Stanley on or about 01/12/2026 on the NASDAQ, with an aggregate market value of $36,069.00. The filing notes that 66,776,006 shares of Verastem common stock were outstanding.
The 5,039 shares to be sold were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, Inc. For additional context, during the past three months Daniel Calkins sold 80 Verastem shares on 12/24/2025 for gross proceeds of $628.80.
Verastem, Inc. insider Daniel Paterson has filed a Form 144 to sell 10,321 shares of Verastem common stock. The planned sale has an aggregate market value of $73,851.00 based on the figures provided, with the shares to be sold through Shareworks by Morgan Stanley on the NASDAQ, with an approximate sale date of 01/12/2026. Verastem had 66,776,006 common shares outstanding according to the notice.
The 10,321 shares proposed for sale were acquired on 01/10/2025 through the vesting of a restricted stock unit award from Verastem, with the same date listed as the payment date and the consideration described as N/A. The filing also lists multiple prior sales of Verastem securities by Daniel Paterson over the past three months, including 3,299 shares sold on 11/03/2025 for $32,146.00 and 2,000 shares sold on 12/11/2025 for $20,000.00.